Immunotherapy in lung cancer. [Review]

MedStar author(s):
Citation: Journal of Surgical Oncology. 123(3):718-729, 2021 Mar.PMID: 33595888Institution: MedStar Washington Hospital CenterDepartment: Hematology/Oncology | Medicine/General Internal MedicineForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2021ISSN:
  • 0022-4790
Name of journal: Journal of surgical oncologyAbstract: Immunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become standards of care for advanced stage disease. They have also shown promise in earlier-stage disease as complements to radiation or surgery, offering the potential for durable, meaningful survival gains. Copyright (c) 2020 Wiley Periodicals LLC.All authors: Farid S, Liu SV, Montenegro GBFiscal year: FY2021Digital Object Identifier: Date added to catalog: 2021-03-10
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 33595888 Available 33595888

Immunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become standards of care for advanced stage disease. They have also shown promise in earlier-stage disease as complements to radiation or surgery, offering the potential for durable, meaningful survival gains. Copyright (c) 2020 Wiley Periodicals LLC.

English

Powered by Koha